CARDIAUVERGNE is a heart failure telemonitoring system at Clermont-Ferrand's hospital. The aim of this study is to analyze the prognosis and evolution of patients after exclusion of telemonitoring. The patients were included from 1st January 2023 to 31st December 2024 and the monitoring was terminated for end of eligibility according to the French health authority criteria.
After an episode of heart failure, patients have been included in a telemonitoring program in order to reduce rehospitalizations for heart failure and improve follow-up. On a daily basis, the patients weigh themselves on connected scales which enables a team of dedicated nurses to follow them closely. If need be they can call the patient, ask for a blood exam and adapt their prescription. Indeed, if remote support is insufficient, patients can be hospitalized prematurely and so decrease the duration of hospital care. The inclusion criteria correspond to either an episode of heart failure in the last 12 months or dyspnea at least New York Heart Association (NYHA) 2 with NT-proBNP over 1000pg/mL. The follow up is renewed every 6 months. Patients are excluded from monitoring when criteria are no longer fulfilled. As these characteristics have been chosen empirically, our aim is to see if patients no longer presenting these standards have indeed a low chance of bad evolution. Information is gathered from their medical record at inclusion, exclusion and 1 year after exclusion. A short phone call is made after 1 year of exclusion, to appreciate their evolution and gather information concerning their symptoms, treatments ...
Study Type
OBSERVATIONAL
Enrollment
130
CHU Clermont-Ferrand
Clermont-Ferrand, France
RECRUITINGComposite criterion defined by the occurrence within one year following the end of remote monitoring of either cardiovascular death or heart failure worsening (hospitalization or unscheduled visit for heart failure)
Time frame: From telemonitoring exclusion up to a year after
Amount of medical appointments
General practician and cardiology consultations
Time frame: From telemonitoring exclusion up to a year after
Natriuretic peptides, NTproBNP, evolution
NTproBNP comparison at inclusion, exclusion and a year after exclusion for monitoring
Time frame: From inclusion until a year after exclusion
Number of patients that could theoretically be re-included during follow up
Time frame: From telemonitoring exclusion up to a year after
Determination of potential patient profiles more suitable to discontinue remote monitoring
Time frame: From inclusion up to a year after telemonitoring exclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.